Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Lock

Showing results (121-130 of 220) with videos related to

Pageof 22
Sort By:
BMJ Open|August 11, 2018
Protocol for the avatar acceptability study: a multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia and New ZealandClaire E Wakefield, Emma L Doolan, Joanna E Fardell, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
British Journal of Cancer|November 27, 2001
MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cellsA E Peaston, M Gardaneh, A V Franco, et al.
Ebiomedicine|November 3, 2018
The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer CareC E Wakefield, E L Doolan, J E Fardell, et al.
Haematologica|January 26, 2019
Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemiaLaurence C Cheung, Mark N Cruickshank, Anastasia M Hughes, et al.
Pediatric Blood & Cancer|May 7, 2009
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing programNino Keshelava, Peter J Houghton, Christopher L Morton, et al.
Blood Cancer Journal|September 7, 2023
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemiaKinjal Shah, Ahmad Nasimian, Mehreen Ahmed, et al.
Pediatric Blood & Cancer|October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
JCI Insight|April 29, 2016
Synergism of FAK and tyrosine kinase inhibition in Ph<sup>+</sup> B-ALLMichelle L Churchman, Kathryn Evans, Jennifer Richmond, et al.
British Journal of Haematology|January 26, 2008
A xenograft model of infant leukaemia reveals a complex MLL translocationMichelle J Henderson, Seoyeon Choi, Alex H Beesley, et al.
Pageof 22

Showing results (121-130 of 220) with videos related to

Sort By:
Pageof 22
BMJ Open|August 11, 2018
Protocol for the avatar acceptability study: a multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia and New ZealandClaire E Wakefield, Emma L Doolan, Joanna E Fardell, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
British Journal of Cancer|November 27, 2001
MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cellsA E Peaston, M Gardaneh, A V Franco, et al.
Ebiomedicine|November 3, 2018
The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer CareC E Wakefield, E L Doolan, J E Fardell, et al.
Haematologica|January 26, 2019
Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemiaLaurence C Cheung, Mark N Cruickshank, Anastasia M Hughes, et al.
Pediatric Blood & Cancer|May 7, 2009
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing programNino Keshelava, Peter J Houghton, Christopher L Morton, et al.
Blood Cancer Journal|September 7, 2023
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemiaKinjal Shah, Ahmad Nasimian, Mehreen Ahmed, et al.
Pediatric Blood & Cancer|October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
JCI Insight|April 29, 2016
Synergism of FAK and tyrosine kinase inhibition in Ph<sup>+</sup> B-ALLMichelle L Churchman, Kathryn Evans, Jennifer Richmond, et al.
British Journal of Haematology|January 26, 2008
A xenograft model of infant leukaemia reveals a complex MLL translocationMichelle J Henderson, Seoyeon Choi, Alex H Beesley, et al.
Pageof 22